# DiaMedica Therapeutics Inc. (DMAC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $6.75, market value $364 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). DiaMedica Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 728.0×**. Each dollar of revenue is priced at 728.0×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 9.5×**. The shares trade at 9.5× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -8.7%** (5-yr avg -16.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -58.4%**. Return on equity is negative because earnings are negative.
- **Return on assets: -9.3%**. Each dollar of assets produces -9.3% of profit.

## Growth
- **EPS growth (1 yr): -16.7%**. Earnings per share fell 16.7%.

## Financial health
- **Interest coverage: -614.6×**. Operating profit covers interest only -614.6×: fragile.
- **Current ratio: 11.81** (quick 11.81). Current assets cover the next year's liabilities 11.81 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. DiaMedica Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 25.7%** (YTD -15.2%, 3-mo 19.7%). The shares are up 25.7% over twelve months including dividends.
- **From 52-week high: -35.2%** (28.7% above the low). Trading 35% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 1.62** (volatility 59%). Beta of 1.62 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DMAC · Page: https://foliofundamentals.com/stocks/dmac

Not investment advice.